6 completed, 1 active not recruiting, 1 available, 1 recruiting. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Recruiting 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Sellas Life Sciences Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML SLS009, venetoclax, azacitidine - Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | Sellas Life Sciences Group | 160 | 2021-05-10 | 2026-09-03 |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 Galinpepimut-S, Azacitidine, Venetoclax - Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Sellas Life Sciences Group | 127 | 2021-02-08 | 2025-10-01 |
| Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers galinpepimut-S, pembrolizumab, Montanide - Acute Myelogenous Leukemia, Ovarian Cancer | Phase 1 / Phase 2 | Completed | Sellas Life Sciences Group | 26 | 2019-09-30 | 2024-11-19 |
| Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients NeuVax vaccine, Trastuzumab, GM-CSF - Breast Cancer | Phase 2 | Completed | Cancer Insight, LLC | 100 | 2014-10-01 | 2023-12-12 |
| Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Herceptin, NeuVax vaccine, GM-CSF - Breast Cancer | Phase 2 | Completed | George E. Peoples | 275 | 2013-05-21 | 2020-12-02 |
| WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation Galinpepimut-S, GM-CSF, Montanide - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Sellas Life Sciences Group | 20 | 2013-04-01 | 2024-09-19 |
| WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Galinpepimut-S, GM-CSF, Montanide - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | Sellas Life Sciences Group | 22 | 2011-01-14 | 2024-11-19 |
| Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy Galinpepimut-S + Montanide + GM-CSF, Montanide + GM-CSF - Malignant Pleural Mesothelioma | Phase 2 | Completed | Sellas Life Sciences Group | 41 | 2010-12-21 | 2024-10-09 |
| Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS Galinpepimut-S - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Available | Sellas Life Sciences Group | 2026-04-24 |
Leukemia, Myeloid, Acute (5) · Breast Neoplasms (2) · Hematologic Neoplasms (2) · Pathologic Complete Response (2) · Breast Neoplasms, Male (1) · Colorectal Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Mesothelioma, Malignant (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Ovarian Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
Granulocyte-Macrophage Colony-Stimulating Factor (7) · sargramostim (6) · Monatide (IMS 3015) (5) · Azacitidine (2) · HER2 peptide (369-377) (2) · Trastuzumab (2) · venetoclax (2) · Bortezomib (1) · Cytarabine (1) · Decitabine (1) · Immunomodulating Agents (1) · Lenalidomide (1) · Observation (1) · Proteasome Inhibitors (1) · Receptor Protein-Tyrosine Kinases (1)
United States (8) · China (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1) · Poland (1) · Serbia (1) · Spain (1) · Taiwan (1)
David J Chung, MD, PhD (1) · Dragan Cicic, MD (1) · Guenther Koehne, MD, PhD (1) · Marjorie Zauderer, MD (1) · Nicholas J Sarlis, MD, PhD (1) · Peter Maslak, MD (1)